Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aflibercept + pranoprofen
- Development stage
- Phase 4
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravitreal, Ophthalmic, Topical
01
Overview
Aflibercept + pranoprofen is a combination therapy used in ophthalmology, specifically studied for the treatment of choroidal neovascularization (CNV) in exudative age-related macular degeneration (AMD). Aflibercept is a recombinant fusion protein that acts as a decoy receptor for vascular endothelial growth factor (VEGF), thereby inhibiting abnormal blood vessel growth and leakage in the retina. Pranoprofen is a topical nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes, reducing inflammation. The combination involves intravitreal injection of aflibercept with adjunctive topical administration of 0.1% pranoprofen eye drops. Clinical studies suggest this combination may act synergistically to improve anatomical outcomes such as central retinal thickness and potentially reduce the number of required aflibercept injections, though no significant additional benefit on visual acuity over monotherapy has been demonstrated[1][2][3][4].
- Other names
- aflibercept plus pranoprofenIVA plus pranoprofen
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGF (Placental Growth Factor)VEGFA (Vascular endothelial growth factor A)VEGFB (Vascular endothelial growth factor B)
Beyond the preview
Go deeper on aflibercept + pranoprofen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aflibercept + pranoprofen.